Serum potassium predicts time to blood pressure response among African Americans with hypertensive nephrosclerosis

Journal of Human Hypertension

Volumn 27, Issue 6, 2013, Pages 393-396

  Bhalla, M ^a   Aziz, H ^a,b   Richard, E ^a,c   Lipkowitz, M S ^d   Bhatnagar, V ^a,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b SAN DIEGO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

antihypertensives; blood pressure; nephrosclerosis; serum potassium; survival analysis

Indexed keywords

AMLODIPINE; METOPROLOL; POTASSIUM; RAMIPRIL;

ADULT; AFRICAN AMERICAN; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; NEPHROSCLEROSIS; POTASSIUM BLOOD LEVEL; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENOVASCULAR HYPERTENSION; TREATMENT RESPONSE;

AFRICAN AMERICANS; ANTIHYPERTENSIVE AGENTS; ARTERIAL PRESSURE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION, RENAL; MALE; MIDDLE AGED; NEPHROSCLEROSIS; POTASSIUM; PREDICTIVE VALUE OF TESTS; TIME FACTORS;

EID: 84877590384     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2012.47     Document Type: Article

References (26)

1. Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE, Roccella EJ. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension 2008; 52: 818-827.
2. Hall WD, Ferrario CM, Moore MA, Hall JE, Flack JM, Cooper W et al. Hypertensionrelated morbidity and mortality in the southeastern United States. Am J Med Sci 1997; 313: 195-209.
3. Hertz RP, Unger AN, Cornell JA, Saunders E. Racial disparities in hypertension prevalence, awareness, and management. Arch Intern Med 2005; 165: 2098-2104.
4. Wright Jr JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. Jama 2002; 288: 2421-2431.
5. Gu Q, Burt VL, Paulose-Ram R, Yoon S, Gillum RF. High blood pressure and cardiovascular disease mortality risk among U.S. adults: the third National Health and Nutrition Examination Survey mortality follow-up study. Ann Epidemiol 2008; 18: 302-309.
6. Watson RL, Langford HG. Weight, urinary electrolytes and blood pressure - results of several community based studies. J Chronic Dis 1982; 35: 909-918.
7. Khaw KT, Barrett-Connor E. The association between blood pressure, age, and dietary sodium and potassium: a population study. Circulation 1988; 77: 53-61.
8. Patki PS, Singh J, Gokhale SV, Bulakh PM, Shrotri DS, Patwardhan B. Efficacy of potassium and magnesium in essential hypertension: a double-blind, placebo controlled, crossover study. Bmj 1990; 301: 521-523.
9. Siani A, Strazzullo P, Russo L, Guglielmi S, Iacoviello L, Ferrara LA et al. Controlled trial of long term oral potassium supplements in patients with mild hypertension. Br Med J (Clin Res Ed) 1987; 294: 1453-1456.
10. Svetkey LP, Yarger WE, Feussner JR, DeLong E, Klotman PE. Double-blind, placebocontrolled trial of potassium chloride in the treatment of mild hypertension. Hypertension 1987; 9: 444-450.
11. D'Elia L, Barba G, Cappuccio FP, Strazzullo P. Potassium intake, stroke, and cardiovascular disease a meta-analysis of prospective studies. J Am Coll Cardiol 2011; 57: 1210-1219.
12. Yang Q, Liu T, Kuklina EV, Flanders WD, Hong Y, Gillespie C et al. Sodium and potassium intake and mortality among US adults: prospective data from the Third National Health and Nutrition Examination Survey. Arch Intern Med 2011; 171: 1183-1191.
13. Wright Jr JT, Agodoa L, Contreras G, Greene T, Douglas JG, Lash J et al. Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch Intern Med 2002; 162: 1636-1643.
14. Wright Jr JT, Kusek JW, Toto RD, Lee JY, Agodoa LY, Kirk KA et al. Design and baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Control Clin Trials 1996; 17: 3S-16S.
15. Lee J, Aziz H, Liu L, Lipkowitz M, O'Connor DT, Richard E et al. Beta(1)-adrenergic receptor polymorphisms and response to beta-blockade in the African-American study of kidney disease and hypertension (AASK). Am J Hypertens 2011; 24: 694-700.
16. Hosmer DW, Lemeshow S, May S. Applied Survival Analysis: Regression Modeling of Time-to-Event Data. 2nd edn. Wiley-Interscience: Hoboken, NJ, 2008.
17. Sudhir K, Forman A, Yi SL, Sorof J, Schmidlin O, Sebastian A et al. Reduced dietary potassium reversibly enhances vasopressor response to stress in African Americans. Hypertension 1997; 29: 1083-1090.
18. Bianchetti MG, Weidmann P, Beretta-Piccoli C, Ferrier C. Potassium and norepinephrine- or angiotensin-mediated pressor control in pre-hypertension. Kidney Int 1987; 31: 956-963.
19. Lawton WJ, Fitz AE, Anderson EA, Sinkey CA, Coleman RA. Effect of dietary potassium on blood pressure, renal function, muscle sympathetic nerve activity, and forearm vascular resistance and flow in normotensive and borderline hypertensive humans. Circulation 1990; 81: 173-184.
20. Korgaonkar S, Tilea A, Gillespie BW, Kiser M, Eisele G, Finkelstein F et al. Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study. Clin J Am Soc Nephrol 2010; 5: 762-769.
21. Hayes J, Kalantar-Zadeh K, Lu JL, Turban S, Anderson JE, Kovesdy CP. Association of hypo- and hyperkalemia with disease progression and mortality in males with chronic kidney disease: the role of race. Nephron Clin Pract 2012; 120: c8-16.
22. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Urinary and serum electrolytes in untreated black and white hypertensives. J Chronic Dis 1987; 40: 839-847.
23. Gibbs CR, Beevers DG, Lip GY. The management of hypertensive disease in black patients. QJM 1999; 92: 187-192.
24. Benowitz NL. Antihypertensive agents. In: Katzung BG, Masters SB, Trevor AJ (eds). Basic & Clinical Pharmacology. Mc Graw Hill: New York, NY, 2007.
25. Cummins CL, Wu CY, Benet LZ. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin Pharmacol Ther 2002; 72: 474-489.
26. Bhatnagar V, O'Connor DT, Schork NJ, Salem RM, Nievergelt CM, Rana BK et al. Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial. J Hypertens 2007; 25: 2082-2092.